# Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

> **NCT01940341** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 426 (actual)

## Conditions studied

- HBeAg-negative Chronic Hepatitis B

## Interventions

- **DRUG:** TAF
- **DRUG:** TDF
- **DRUG:** TAF Placebo
- **DRUG:** TDF Placebo

## Key facts

- **NCT ID:** NCT01940341
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-12
- **Primary completion:** 2015-09-30
- **Final completion:** 2022-08-31
- **Target enrollment:** 426 (ACTUAL)
- **Last updated:** 2023-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01940341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01940341, "Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01940341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*